Clinical trials
Rare Cancer clinical trials
Below are recruiting rare cancer clinical trials, each written for real people, not researchers. We’re tracking 50 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05350761Recruiting
Study rare tumors and inherited cancer risk in families
This study looks at people who have rare or unusual cancers or who may have an inherited (family) risk for cancer. It helps researchers learn what genetic or other factors might be involved by collecting family history and medical records, including pathology slides.
Bethesda, MarylandAges Any age - NCT07731880Recruiting
SmartMatch Study for Rare Gynecologic Cancers
This study tests a new approach called SmartMatch that looks at the unique traits of your tumor to find the best treatment for you. The goal is to see if this personalized approach is feasible and helpful for people with rare gynecologic cancers.
Seattle, WashingtonAges 18 years+ - NCT07292298RecruitingPhase 2
Rectal cancer brachytherapy after treatment to avoid surgery
This trial tests a special type of internal radiation (brachytherapy) for people with low-lying rectal cancer that did not fully go away after standard chemoradiation and chemotherapy. The goal is to shrink the remaining tumor enough to avoid major surgery like removing the rectum or colostomy.
Aurora, ColoradoAges 18–100 - NCT05872204RecruitingPhase 2
Abemaciclib plus letrozole for rare ER-positive ovarian cancer
This trial tests whether abemaciclib with letrozole can slow or shrink certain rare ovarian cancers that have estrogen receptors. It may help people whose cancer has come back and can be measured on scans, with extra required tissue and blood tests.
Liège, LiègeAges 18 years+ - NCT03210935Recruiting
National registry for rare skin cancer diagnoses
This trial is a French national database that collects information from people with certain rare skin cancers. It may help researchers better understand these cancers and improve future care, using real-world patient data.
Dijon, DijonAges Any age - NCT06408441Recruiting
EHE registry for rare adult cancers
This study collects information from European hospitals on people with epithelioid hemangioendothelioma (EHE), a rare tumor that grows in blood vessels. Joining this registry helps doctors learn more about the disease and improve care for others.
Graz, GrazAges 18 years+ - NCT06541652Recruiting
Study of rare liver cancers in France
This study looks at people with rare types of liver cancer to learn more about the disease. If you have one of these rare liver cancers, your information could help doctors understand these cancers better.
AmiensAges 18 years+ - NCT06563999RecruitingPhase 2
Study of new drugs for stage III lung cancer with rare gene changes
This trial tests whether giving treatment before surgery (neoadjuvant therapy) can help people with stage III lung cancer that has certain rare gene changes. The goal is to see if this approach can shrink the tumor enough to allow surgery.
Guangzhou, GuangdongAges 18–75 - NCT07147465Recruiting
Using gene sequencing to improve cancer care
This study looks at how well a special type of gene testing (called sequencing) works for people with cancer. It aims to learn if this test helps doctors choose better treatments.
LyonAges Any age - NCT06638931RecruitingPhase 2
Nivolumab for rare solid tumors with high PD-L1
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
Fortaleza, CearáAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT07374692Recruiting
Study of treatments for advanced brain and spinal cord tumors
This study looks at how different treatments work for people with advanced brain or spinal cord tumors that have come back. It helps doctors learn more about these tumors and how to better treat them.
Bethesda, MarylandAges 15–120 - NCT06684327RecruitingPhase 2
Study of three chemotherapy drugs for rare advanced cancers
This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07089992RecruitingPhase 2
Pembrolizumab for ultra-rare sarcoma types
This trial tests whether pembrolizumab, an immunotherapy that helps your immune system attack cancer cells, can shrink or slow growth in several ultra-rare sarcoma types that have come back or spread. It may be an option if your previous treatments have stopped working.
Basking Ridge, New JerseyAges 18 years+ - NCT04777175Recruiting
Looking at immunotherapy for lung cancer with rare gene mutations
This study looks back at patients with advanced non-small cell lung cancer who have specific rare gene changes (mutations). It aims to see how well immunotherapy works for people with these exact mutations.
Changsha, HunanAges 18–75 - NCT07662681RecruitingPhase 1/Phase 2
Camrelizumab plus famitinib for rare head and neck cancers
This trial tests a combination of two drugs—camrelizumab (an immunotherapy) and famitinib (a targeted therapy)—for people with rare head and neck tumors that cannot be removed by surgery or have spread. It may be an option if you have not had a prior PD-1 inhibitor and have had at most one prior systemic treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05203250Recruiting
Registry for people treated with heavy particles at CNAO
This registry collects information from people who received heavy particle treatments at the CNAO center. It helps researchers understand outcomes over time, as long as you can understand the study and agree in writing.
PaviaAges Any age - NCT05800340RecruitingPhase 2
Immunotherapy before surgery for certain rare lung cancer mutations
This Phase 2 study tests an immunotherapy treatment given before surgery for people with stage IIB to IIIB non-small cell lung cancer (NSCLC) that has specific rare “driver” gene changes. The goal is to shrink the cancer and improve outcomes by treating it earlier with the immune system.
Guanzhou, GuangdongAges 18 years+ - NCT06161532RecruitingPhase 2
Sacituzumab govitecan with or without atezolizumab for rare GU cancers
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Bethesda, MarylandAges 18–120 - NCT03739827Recruiting
Study rare solid tumors and collect your health samples
This study follows people (and sometimes family members) connected to rare solid tumors and collects health information and samples (biospecimens). It helps researchers understand how these cancers develop and builds resources for future research, which may benefit you by contributing to better tailored care for rare cancers.
Bethesda, MarylandAges 4 weeks+ - NCT06041503RecruitingPhase 2
Treating rare bladder and testicular cancers with targeted therapy
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) for people with certain rare cancers of the urinary tract or testicles. The goal is to see if these treatments can shrink tumors or stop them from growing.
Bethesda, MarylandAges 18–120 - NCT06250595Recruiting
European rare blood disorder registry
This study is building a registry of people with rare blood diseases. By joining, you help doctors learn more about these conditions and improve future care.
Barcelona, CataloniaAges Up to 100 years - NCT04423185RecruitingPhase 2
Precision medicine trial for rare advanced solid tumors
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
BeijingAges 18 years+ - NCT05722886RecruitingPhase 2/Phase 3
Screening trial for rare cancer gene changes in existing medicines
This trial checks whether existing cancer medicines can help people whose tumors have specific “gene changes” (mutations). You may be assigned to a treatment arm that matches your tumor’s gene results after fresh biopsy and blood testing.
BelfastAges Any age
Hear when a new Rare Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rare cancer?
- Yes. Clin2 currently lists 50 recruiting rare cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rare cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rare cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.